Off-label drug use is common. But off-label of chemotherapy is utterly reckless

Reckless use of chemo is robbing cancer patients

Two weeks ago, I told you about Sarah Hershberger, the 11-year-old Amish girl whose parents took her out of the country to get her treated for her cancer — without chemo.

The mainstream media lit up with concern for the girl — at the hands of these dangerous parents of hers.

How dare they risk her life by denying her chemo!

Are they kidding?!

In the past few years, we’ve discovered that chemo frequently causes secondary cancers, can actually FEED tumors, and that chemo traumatizes the brain for years.

And still, the mainstream wants to force this little girl — and millions of others — to take this dangerous “treatment” at all costs.

Now it turns out, “at all costs” may be exactly what doctors are thinking when they prescribe chemo.

Oncologists gone wild

Believe it or not, even with all the dangers and risks, mainstream medicine has decided it’s okay to introduce off-label use of chemo.

Off-label use is essentially unregulated use. It means the FDA hasn’t approved — or even studied — the drug for the use the doctor prescribes it for.

That’s why this new information on chemo is so shocking.

Researchers followed prescribing records of 10 chemotherapy drugs. They found that oncologists prescribed the drugs off-label in nearly one-third of all cases!

That’s outrageous!

Now, in many of those cases, doctors followed guidelines of the National Comprehensive Care Network. But as Reuters notes, some researchers have criticized NCCN for possible conflicts of interest. So this is a slippery set of guidelines, at best.

But then there’s the “loose cannon” 10 percent.

That’s right — doctors are working on a hunch in 10% of these cases. And that’s giving doctors the benefit of the doubt. In many instances, they prescribe chemo knowing the odds of success are nil.

But they probably think they can give the patient some hope and the payday isn’t too shabby.

So — 10 percent — if you’re thinking that doesn’t sound like much, hang on to your hat. In the course of one year, that meager 10 percent accounted for $2.5 billion in medical bills!

One researcher told Reuters that cancer patients and their doctors are “willing to try things where there isn’t as much data as you would like.” She says they’re, “looking for anything with a benefit.”

ANYthing? Well…no.

Most oncologists would never even consider the benefits of intravenous ascorbic acid. IAA has plenty of successful cancer case studies to back up its use. But mainstreamers dismiss it as quackery.

And yet, these doctors are willing to risk billions of their patients’ dollars on brutal chemotherapies that don’t even have case study support.

So… Who’s a quack now?

Sources:
“Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists” Journal of Clinical Oncology, Published online ahead of print, 2/19/13, jco.ascopubs.org

“Almost one-third of chemotherapy used ‘off-label'” Andrew M. Seaman, Reuters Health, 2/19/13, reuters.com

Get urgent health alerts, warnings and insights delivered straight to your inbox